Insmed (NASDAQ:INSM) Stock Rating Reaffirmed by Truist Financial

Truist Financial reaffirmed their buy rating on shares of Insmed (NASDAQ:INSMFree Report) in a research report sent to investors on Thursday, Benzinga reports. They currently have a $48.00 price target on the biopharmaceutical company’s stock.

INSM has been the topic of a number of other research reports. StockNews.com raised shares of Insmed from a sell rating to a hold rating in a report on Tuesday, May 14th. UBS Group began coverage on Insmed in a research note on Tuesday, February 27th. They issued a buy rating and a $46.00 price objective for the company. Morgan Stanley boosted their target price on Insmed from $40.00 to $43.00 and gave the stock an overweight rating in a research report on Friday, May 10th. Wolfe Research initiated coverage on Insmed in a research report on Thursday, February 15th. They issued an outperform rating and a $42.00 price target for the company. Finally, The Goldman Sachs Group boosted their price objective on shares of Insmed from $40.00 to $49.00 and gave the stock a buy rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of Moderate Buy and a consensus target price of $44.71.

View Our Latest Stock Analysis on INSM

Insmed Price Performance

INSM opened at $24.77 on Thursday. The business has a 50 day simple moving average of $26.27 and a 200-day simple moving average of $27.09. Insmed has a 12 month low of $18.31 and a 12 month high of $32.00.

Insmed (NASDAQ:INSMGet Free Report) last released its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.16. The business had revenue of $75.50 million during the quarter, compared to analyst estimates of $77.76 million. Insmed’s revenue was up 15.8% compared to the same quarter last year. During the same period last year, the business posted ($1.17) EPS. On average, equities research analysts predict that Insmed will post -4.52 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, insider John Drayton Wise sold 5,088 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $25.47, for a total transaction of $129,591.36. Following the sale, the insider now owns 123,259 shares in the company, valued at $3,139,406.73. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In related news, insider John Drayton Wise sold 5,088 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $25.47, for a total transaction of $129,591.36. Following the transaction, the insider now directly owns 123,259 shares in the company, valued at $3,139,406.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Roger Adsett sold 7,857 shares of Insmed stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $25.50, for a total value of $200,353.50. Following the completion of the sale, the chief operating officer now owns 155,220 shares of the company’s stock, valued at approximately $3,958,110. The disclosure for this sale can be found here. Insiders sold a total of 46,231 shares of company stock worth $1,177,186 over the last ninety days. 4.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Insmed

Large investors have recently bought and sold shares of the stock. International Assets Investment Management LLC purchased a new position in shares of Insmed in the 4th quarter worth $25,000. EntryPoint Capital LLC acquired a new position in shares of Insmed during the first quarter worth about $33,000. Fidelis Capital Partners LLC purchased a new position in Insmed in the 1st quarter worth approximately $34,000. Headlands Technologies LLC purchased a new position in shares of Insmed in the first quarter valued at $59,000. Finally, Quarry LP acquired a new stake in Insmed during the 4th quarter valued at $116,000.

About Insmed

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read More

Analyst Recommendations for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.